Compile Data Set for Download or QSAR
maximum 50k data
Found 306 of ec50 for UniProtKB: A0A024RD33
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US10597366, Compound 64 | US9896418, Compound 64)
Affinity DataEC50:  1nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US10597366, Compound 64 | US9896418, Compound 64)
Affinity DataEC50:  1nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372992(US10597366, Compound 64 | US9896418, Compound 64)
Affinity DataEC50:  1nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566629(3-fluoro-5-(((1R,2S,2aS)-1,2,3,3,4,4-hexafluoro- 2...)
Affinity DataEC50:  2nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373015(US10597366, Compound 185 | US9896418, Compound 185)
Affinity DataEC50:  4nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373015(US10597366, Compound 185 | US9896418, Compound 185)
Affinity DataEC50:  4nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373015(US10597366, Compound 185 | US9896418, Compound 185)
Affinity DataEC50:  4nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US10597366, Compound 158 | US9896418, Compound 158)
Affinity DataEC50:  6nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US10597366, Compound 158 | US9896418, Compound 158)
Affinity DataEC50:  6nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US10597366, Compound 9 | US9896418, Compound 9)
Affinity DataEC50:  6nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US10597366, Compound 9 | US9896418, Compound 9)
Affinity DataEC50:  6nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373004(US10597366, Compound 158 | US9896418, Compound 158)
Affinity DataEC50:  6nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566616(3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a- hy...)
Affinity DataEC50:  6nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566616(3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a- hy...)
Affinity DataEC50:  6nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372966(US10597366, Compound 9 | US9896418, Compound 9)
Affinity DataEC50:  6nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373041(US10597366, Compound 292 | US9896418, Compound 292)
Affinity DataEC50:  6.20nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373042(US10597366, Compound 273 | US9896418, Compound 273)
Affinity DataEC50:  6.20nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373041(US10597366, Compound 292 | US9896418, Compound 292)
Affinity DataEC50:  6.20nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373042(US10597366, Compound 273 | US9896418, Compound 273)
Affinity DataEC50:  6.20nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373041(US10597366, Compound 292 | US9896418, Compound 292)
Affinity DataEC50:  6.20nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373042(US10597366, Compound 273 | US9896418, Compound 273)
Affinity DataEC50:  6.20nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566628((R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-...)
Affinity DataEC50:  7nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373005(US10597366, Compound 159 | US9896418, Compound 159)
Affinity DataEC50:  7nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373005(US10597366, Compound 159 | US9896418, Compound 159)
Affinity DataEC50:  7nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373005(US10597366, Compound 159 | US9896418, Compound 159)
Affinity DataEC50:  7nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM282572((R)-3-((4-(difluoromethyl)-2,2-difluoro-3-hydroxy-...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM282656(4-(Difluoromethyl)-5-(3,5-difluorophenoxy)-2,2- di...)
Affinity DataEC50:  9nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566615(3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy- 2,2...)
Affinity DataEC50:  10nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566630(3-fluoro-5-(((1R,2R,2aS)-1,2,3,3,4,4-hexafluoro- 2...)
Affinity DataEC50:  11nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373006(US10597366, Compound 161 | US9896418, Compound 161)
Affinity DataEC50:  11nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373006(US10597366, Compound 161 | US9896418, Compound 161)
Affinity DataEC50:  11nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373006(US10597366, Compound 161 | US9896418, Compound 161)
Affinity DataEC50:  11nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM566614(3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1- met...)
Affinity DataEC50:  13nMAssay Description:The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. About 7500 786-O cells were...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373016(US10597366, Compound 186 | US9896418, Compound 186)
Affinity DataEC50:  13nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373016(US10597366, Compound 186 | US9896418, Compound 186)
Affinity DataEC50:  13nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373016(US10597366, Compound 186 | US9896418, Compound 186)
Affinity DataEC50:  13nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM438062(US10597366, Compound 317 | US10597366, Compound 32...)
Affinity DataEC50:  14nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373050(US10597366, Compound 316 | US9896418, Compound 316...)
Affinity DataEC50:  14nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM282685(3-((4-(Difluoromethyl)-2,2-difluoro-3-hydroxy-1,1-...)
Affinity DataEC50:  14nMAssay Description:About 7500 of 786-O cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373050(US10597366, Compound 316 | US9896418, Compound 316...)
Affinity DataEC50:  14nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373028(US10597366, Compound 233 | US9896418, Compound 233)
Affinity DataEC50:  15nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US10597366, Compound 11 | US9896418, Compound 11)
Affinity DataEC50:  15nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US10597366, Compound 11 | US9896418, Compound 11)
Affinity DataEC50:  15nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM372972(US10597366, Compound 11 | US9896418, Compound 11)
Affinity DataEC50:  15nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373028(US10597366, Compound 233 | US9896418, Compound 233)
Affinity DataEC50:  15nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373028(US10597366, Compound 233 | US9896418, Compound 233)
Affinity DataEC50:  15nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Peloton Therapeutics

US Patent
LigandPNGBDBM373031(US10597366, Compound 236 | US9896418, Compound 236)
Affinity DataEC50:  16nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 306 total ) | Next | Last >>
Jump to: